Siren Biotechnology is pioneering a novel approach to cancer treatment by integrating two transformative therapeutic technologies: adeno-associated virus (AAV) gene therapy and cytokine immunotherapy. This innovative combination aims to create a universal AAV immuno-gene therapy that can be utilized across various solid tumors, significantly streamlining clinical development and manufacturing processes. The therapy is designed to deliver engineered cytokines directly to tumor sites, enabling targeted destruction of tumor cells while simultaneously activating the immune system. This dual action not only addresses the immediate threat posed by tumors but also enhances the body's long-term immune response against cancer.

The unique design of Siren's therapy allows for low-dose, localized delivery of cytokines, which mitigates the risks of systemic toxicity often associated with traditional immunotherapies. By ensuring that cytokine expression is self-limiting—ceasing upon tumor cell death—Siren's approach enhances safety and efficacy. Additionally, the therapy is engineered to be effective regardless of pre-existing anti-AAV immunity, a common challenge in systemic AAV therapies. This comprehensive strategy positions Siren Biotechnology at the forefront of cancer treatment innovation, with the potential to significantly improve outcomes for patients suffering from various solid tumors.

United States

Siren Biotechnology is combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.

Cancer

Central Nervous System (CNS)

Eye Diseases

Siren Biotechnology

Brain Cancer

Eye Cancer

Siren Biotechnology Drug #1 (Universal AAV Immuno-Gene Therapy™)

Biologics

Gene Therapy

San Francisco, California, United States of America

California - North

California

Adeno-associated viral vector (AAV)

Antiviral Therapies

Cell Therapies

Therapeutic

Siren Biotechnology

Company Details